Next Generation Sequencing

Lighthouse

Blood-based Biomarkers in Cancer

Liquid biopsy for cancer is non-invasive and easily repeated, permitting molecular profiling and many other purposes with strong accuracy.

Lighthouse

How Does Awareness of Biomarkers Compare to Prevalence?

We compared awareness in oncologists of selected biomarkers to the prevalence of actionable oncogenic mutations across cancers.

Lighthouse

RAS Biomarker Trending and Awareness in Oncologists

We examined RAS/KRAS trending and awareness for oncologists; results track strongly with the history of scientific KRAS advancements.

Lighthouse

NTRK Trending and Awareness in Community Oncologists

We analyzed trending and awareness patterns of NTRK and NTRK-targeting compounds in academic and community oncologists.

Lighthouse

The Value of Molecularly Defined Patient Advocacy Groups

Patient advocacy groups provide support, education, advocacy, and information sharing while including the patient perspective in healthcare.

Lighthouse

Does Every Cancer Patient Get Next Generation Sequencing?

NGS is useful for diagnosis and prognosis but also for treatment decisions and resistance monitoring yet it is not consistently used.